[Synthesis, properties and anti-HIV activity of novel lipophilic 3'-azido-3'-deoxythymidine conjugates containing functional phosphoric linkages]. 2013

N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz

One of the approaches to enhance bioavailability of nucleoside reverse transcriptase HIV inhibitors consists in design of their prodrugs based on 1,3-diacylglycerols, which may simulate nature lipids metabolic pathways promoting the improvement of drug delivery to the target cells. Glycerolipidic AZT conjugates with different functional phosphoric centers were synthesized by H-phosphonate technique in the present work. Study of prepared prodrugs sensibility to the chemical and enzymatic hydrolysis (in buffer solution and under the influence of pancreatic lipase) and also study of their anti-HIV activity on the T-lymphoid human MT-4 cells in regarding to virus HIV-1(899A) strain were carried out.

UI MeSH Term Description Entries
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D018929 Cell Culture Techniques Methods for maintaining or growing CELLS in vitro. Cell Culture,Cell Culture Technique,Cell Cultures,Culture Technique, Cell,Culture Techniques, Cell
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
January 1995, Cellular and molecular biology (Noisy-le-Grand, France),
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
July 1999, Bioorganicheskaia khimiia,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
February 2011, Tetrahedron letters,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
April 1994, Chemistry and physics of lipids,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
December 1994, Journal of medicinal chemistry,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
July 1992, Antiviral research,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
January 2014, Nucleosides, nucleotides & nucleic acids,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
January 1991, Antiviral research,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
January 2011, Bioorganic & medicinal chemistry letters,
N S Shastina, and T Iu Mal'tseva, and L N D'iakova, and O A Lobach, and M S Chataeva, and D N Nosik, and V I Shvetz
January 2004, Nucleosides, nucleotides & nucleic acids,
Copied contents to your clipboard!